CLAG treatment for acute myeloid leukemia after failed first induction
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of chemotherapy drugs called CLAG in patients with acute myeloid leukemia (AML) whose first round of treatment did not work. The goal is to see if this new treatment can help these patients achieve remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute myeloid leukemia (AML).
- Your first round of induction chemotherapy did not lead to remission.
- You do not have a serious infection or major organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment that uses your own immune cells (called CAR-T cells) to fight leukemia, followed by a stem cell transplant to help rebuild your immune system. It is designed for people with acute myeloid leukemia (AML) that has not gone away or has come back after standard treatment.
This trial studies a drug called CLAG-GO (an antibody with chemotherapy drugs attached) in adults with AML that has come back or did not respond to treatment. It aims to improve outcomes for people whose leukemia is persistent, relapsed, or refractory.
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
This Phase 1 trial tests CLN-049 in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or did not respond to treatment. The goal is to find out how well the drug can work and how safe it is in people with limited options.
This Phase 3 trial compares two chemotherapy approaches given first (induction) for people newly diagnosed with AML. It aims to find which option works better and is safer to help achieve remission.
This trial studies a specific chemotherapy plan (called sequential CLAG-Ven) with a gentler “conditioning” treatment before a transplant or donor-based therapy. It may help people with refractory or quickly relapsing acute myeloid leukemia (AML) who have a suitable family or matched donor and can meet certain organ function and infection rules.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.